As a result, we performed an immunotherapy and discovered that in the renal cell carcinoma (GSE67501) and bladder cancer (IMvigor210) datasets, there were notable changes in the immune response effects among the SMARCD3 low and high-expression groups. Here, SMARCD3 is linked to urinary bladder carcinoma.